Ryosuke Kuribayashi

Mass spectrometric glycoform profiling of the innovator and biosimilar erythropoietin and darbepoetin by LC/ESI-MS

Akira Harazono, Noritaka Hashii, Ryosuke Kuribayashi et al. · Journal of Pharmaceutical and Biomedical Analysis · 2013 · 50 citations

Biosimilar Erythropoietin, Glycosylation, Medicine +10

Regulation of Generic Drugs in Japan: the Current Situation and Future Prospects

Ryosuke Kuribayashi, Maki Matsuhama, Kenichi Mikami · The AAPS Journal · 2015 · 37 citations · Full text

Drug Safety, Generic Drugs, Future Prospects +10

Rapid evaluation for heterogeneities in monoclonal antibodies by liquid chromatography/mass spectrometry with a column-switching system

Ryosuke Kuribayashi, Noritaka Hashii, Akira Harazono et al. · Journal of Pharmaceutical and Biomedical Analysis · 2012 · 22 citations

Autoimmune Disease, Column-switching System, Bioanalysis +15

Characterization of N‐glycan heterogeneities of erythropoietin products by liquid chromatography/mass spectrometry and multivariate analysis

Noritaka Hashii, Akira Harazono, Ryosuke Kuribayashi et al. · Rapid Communications in Mass Spectrometry · 2014 · 20 citations

Regulatory Considerations of Bioequivalence Studies for Oral Solid Dosage Forms in Japan

Ryosuke Kuribayashi, Tomoko Takishita, Kenichi Mikami · Journal of Pharmaceutical Sciences · 2016 · 20 citations

Bioequivalence Studies, Bioequivalence, Pharmacology +6